Xenon Xe-129
Identification
- Summary
Xenon Xe-129 is as a hyperpolarized contrast agent, it is indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation.
- Generic Name
- Xenon Xe-129
- DrugBank Accession Number
- DB17386
- Background
Hyperpolarized Xenon-129 (Xe-129) is a contrast agent used in the lung's clinical magnetic resonance imaging (MRI). Lung MRIs are challenging due to the low proton density of this tissue, as well as the presence of artifacts due to respiration and cardiovascular pulsation movement and air–tissue interfaces.1,2 The use of hyperpolarized noble gases makes lung MRIs feasible. They undergo a process that increases nuclear polarization up to five orders of magnitude, leading to a higher MRI signal. Helium-3 (He-3) is the one most commonly used due to its strong signal and favorable safety profile, but its use in other applications has affected its availability.1 Xe-129 has a lower cost, and adverse effects are normally resolved shortly after administration.2 In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.7 Hyperpolarized Xe-129 is chemically identical to non-polarized Xe-129, and xenon is a clear, colorless, monoatomic, inert, stable, noble gas.6
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 128.9048
Monoisotopic: 128.90478086 - Chemical Formula
- Xe
- Synonyms
- Xenon xe-129m
- Xenon-129m
- Xenon, isotope of mass 129
- Xenon, isotope of mass 129m(8.88 d)
- Xenon, xe-129m
- External IDs
- XE-129M
- XENON XE-129
Pharmacology
- Indication
Hyperpolarized Xenon-129 is a contrast agent indicated for use with magnetic resonance imaging (MRI) for the evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.6
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Ventilation of the lung •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
The volume of gas inhaled, the degree of xenon-129 isotopic enrichment, and the degree of hyperpolarization affect the MRI signal obtained with hyperpolarized xenon-129.6 When inhaled for long periods of time, xenon acts as an anesthetic at concentrations higher than 50%. Xenon has also been used in computerized tomography (CT) scans to measure cerebral blood flow.2
- Mechanism of action
The nuclear polarisation of xenon-129 (Xe-129) is increased up to five orders of magnitude in a process called hyperpolarization. This process compensates for the low density of gas compared to that of solid tissue.5
After being inhaled, hyperpolarized xenon-129 (Xe-129) is distributed throughout the ventilated lung. Lung ventilation can be visualized using a multi-nuclear capable magnetic resonance imaging (MRI) scanner with a Xe-129 MRI coil.6
- Absorption
The pharmacokinetic parameters of hyperpolarized xenon-129 are similar to those of non-polarized xenon. Xenon has low solubility; however, it is higher in fatty tissues compared to aqueous tissues and body compartments such as plasma.4,6 A study that modelled the pharmacokinetics of hyperpolarized xenon-129 suggests that 80% is the maximum concentration that can be inhaled. Hyperpolarized xenon-129 delivered through inhalation can be detected in both pulmonary and cerebral tissues.3
- Volume of distribution
Xenon is readily diffusible and able to disperse in the ventilated areas of the lung. There is a small amount of xenon uptake into the pulmonary vessels, followed by distribution to more distal organs.6
- Protein binding
Not available.
- Metabolism
As an inert gas, xenon is not metabolized under normal conditions. It does not have an effect on renal or hepatic function.4
- Route of elimination
Xenon-129 administered through inhalation is eliminated through exhalation.6
- Half-life
Xenon-129 in a 75% Xe/25% N2 gas mixture has an elimination half-life of 14.5 seconds. In a 25% Xe/75% N2 gas mixture, xenon-129 has an elimination half-life of 14.3 seconds.6
- Clearance
Not available.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Toxicity information regarding hyperpolarized Xenon-129 is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as transient hypoxia.6 Symptomatic and supportive measures are recommended. The mutagenic and carcinogenic potential of hyperpolarized Xenon-129 has not been evaluated.6
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Xenoview Gas 75 mL/1L Respiratory (inhalation) Polarean, Inc. 2022-12-23 Not applicable US - Mixture Products
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 9C7571UDT5
- CAS number
- 13965-99-6
- InChI Key
- FHNFHKCVQCLJFQ-YPZZEJLDSA-N
- InChI
- InChI=1S/Xe/i1-2
- IUPAC Name
- (129Xe)xenon
- SMILES
- [129Xe]
References
- Synthesis Reference
Honig, A. (2000). Bulk production and usage of hyperpolarized 129 Xenon. (U.S. Patent No. 6,125,654 A). U.S. Patent and Trademark Office. https://patentimages.storage.googleapis.com/07/b2/0d/d93e5d29439e56/US6125654.pdf
- General References
- Mugler JP 3rd, Altes TA: Hyperpolarized 129Xe MRI of the human lung. J Magn Reson Imaging. 2013 Feb;37(2):313-31. doi: 10.1002/jmri.23844. [Article]
- Liu Z, Araki T, Okajima Y, Albert M, Hatabu H: Pulmonary hyperpolarized noble gas MRI: recent advances and perspectives in clinical application. Eur J Radiol. 2014 Jul;83(7):1282-1291. doi: 10.1016/j.ejrad.2014.04.014. Epub 2014 Apr 30. [Article]
- Wang Y, Dmochowski IJ: An Expanded Palette of Xenon-129 NMR Biosensors. Acc Chem Res. 2016 Oct 18;49(10):2179-2187. doi: 10.1021/acs.accounts.6b00309. Epub 2016 Sep 19. [Article]
- Bajaj T, Cascella M, Borger J: Xenon. . [Article]
- Eddy RL, Parraga G: Pulmonary xenon-129 MRI: new opportunities to unravel enigmas in respiratory medicine. Eur Respir J. 2020 Feb 6;55(2):1901987. doi: 10.1183/13993003.01987-2019. Print 2020 Feb. [Article]
- FDA Approved Drug Products: XENOVIEW (xenon Xe 129 hyperpolarized) for oral inhalation [Link]
- Globe News Wire: FDA Approves Polarean’s XENOVIEW (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation [Link]
- External Links
- ChemSpider
- 8466280
- 2626219
- ChEBI
- 52453
- ChEMBL
- CHEMBL4594411
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gas Respiratory (inhalation) Gas Respiratory (inhalation) 75 mL/1L - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US10583205 No 2020-03-10 2035-02-20 US US11052161 No 2021-07-06 2035-12-29 US
Properties
- State
- Gas
- Experimental Properties
Property Value Source melting point (°C) 161.7 K Bajaj et al. (2022). Xenon, StatPearls Publishing. boiling point (°C) 166.6 K Bajaj et al. (2022). Xenon, StatPearls Publishing. - Predicted Properties
Property Value Source logP 0 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 03, 2023 20:01 / Updated at January 11, 2023 00:13